Literature DB >> 18537262

Synthesis, characterization, and biological evaluation of integrin alphavbeta3-targeted PAMAM dendrimers.

C Andrew Boswell1, Peter K Eck, Celeste A S Regino, Marcelino Bernardo, Karen J Wong, Diane E Milenic, Peter L Choyke, Martin W Brechbiel.   

Abstract

Ligand size and valency strongly influence the receptor uptake and clearance of tumor angiogenesis imaging agents. The structures of successful imaging agents exhibit a high degree of variability, encompassing small monovalent arginine-glycine-aspartic acid (RGD)-containing peptides, multivalent RGD-oligomers, and a monoclonal antibody against integrin alpha-v-beta-3 (alpha-v-beta-3). We have pursued a nanoscale approach to imaging of angiogenesis using rationally designed polyamidoamine (PAMAM) dendrimers covalently adorned with RGD-cyclopeptides. An orthogonal oxime-ligation strategy was applied to chemoselectively effect conjugation of the PAMAM dendrimers with RGD-cyclopeptides for targeting alpha vbeta 3. Fluorescent dyes for optical imaging and chelates for gadolinium-based magnetic resonance (MR) imaging were subsequently appended to create robust multimodal macromolecular imaging agents. Fluorescence microscopy revealed selective binding of the resulting RGD peptide-bearing dendrimer with empty chelates to alpha-v-beta-3-expressing cells, but somewhat reduced selectivity was observed following Gd(III) complexation. The expected incomplete saturation of chelates with Gd(III) ions permitted radiometal complexation, and an in vivo tissue distribution of the resulting agent in M21 melanoma tumor-bearing mice showed mostly renal and reticuloendothelial accumulation, with the tumor:blood ratio peaking (3.30+/-0.03) at 2 h postinjection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18537262      PMCID: PMC2574599          DOI: 10.1021/mp800022a

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  34 in total

1.  RGD peptides and monoclonal antibodies, antagonists of alpha(v)-integrin, enter the cells by independent endocytic pathways.

Authors:  S Castel; R Pagan; F Mitjans; J Piulats; S Goodman; A Jonczyk; F Huber; S Vilaró; M Reina
Journal:  Lab Invest       Date:  2001-12       Impact factor: 5.662

Review 2.  Functional magnetic resonance imaging in oncology for diagnosis and therapy monitoring.

Authors:  Michael V Knopp; Hendrik von Tengg-Kobligk; Peter L Choyke
Journal:  Mol Cancer Ther       Date:  2003-04       Impact factor: 6.261

Review 3.  The structures of integrins and integrin-ligand complexes: implications for drug design and signal transduction.

Authors:  Kay-E Gottschalk; Horst Kessler
Journal:  Angew Chem Int Ed Engl       Date:  2002-10-18       Impact factor: 15.336

4.  3D-micro-MR angiography of mice using macromolecular MR contrast agents with polyamidoamine dendrimer core with reference to their pharmacokinetic properties.

Authors:  H Kobayashi; N Sato; A Hiraga; T Saga; Y Nakamoto; H Ueda; J Konishi; K Togashi; M W Brechbiel
Journal:  Magn Reson Med       Date:  2001-03       Impact factor: 4.668

5.  Integrin alpha(v)beta3 promotes M21 melanoma growth in human skin by regulating tumor cell survival.

Authors:  E Petitclerc; S Strömblad; T L von Schalscha; F Mitjans; J Piulats; A M Montgomery; D A Cheresh; P C Brooks
Journal:  Cancer Res       Date:  1999-06-01       Impact factor: 12.701

6.  Monoclonal antibody-dendrimer conjugates enable radiolabeling of antibody with markedly high specific activity with minimal loss of immunoreactivity.

Authors:  H Kobayashi; N Sato; T Saga; Y Nakamoto; T Ishimori; S Toyama; K Togashi; J Konishi; M W Brechbiel
Journal:  Eur J Nucl Med       Date:  2000-09

7.  Arginine-glycine-aspartic acid (RGD)-peptide binds to both tumor and tumor-endothelial cells in vivo.

Authors:  Sabine Zitzmann; Volker Ehemann; Manfred Schwab
Journal:  Cancer Res       Date:  2002-09-15       Impact factor: 12.701

8.  Macromolecular MRI contrast agents with small dendrimers: pharmacokinetic differences between sizes and cores.

Authors:  Hisataka Kobayashi; Satomi Kawamoto; Sang-Kyung Jo; Henry L Bryant; Martin W Brechbiel; Robert A Star
Journal:  Bioconjug Chem       Date:  2003 Mar-Apr       Impact factor: 4.774

9.  Imaging tumor angiogenesis with contrast ultrasound and microbubbles targeted to alpha(v)beta3.

Authors:  Dilantha B Ellegala; Howard Leong-Poi; Joan E Carpenter; Alexander L Klibanov; Sanjiv Kaul; Mark E Shaffrey; Jiri Sklenar; Jonathan R Lindner
Journal:  Circulation       Date:  2003-06-30       Impact factor: 29.690

10.  Specific targeting of folate-dendrimer MRI contrast agents to the high affinity folate receptor expressed in ovarian tumor xenografts.

Authors:  S D Konda; M Aref; S Wang; M Brechbiel; E C Wiener
Journal:  MAGMA       Date:  2001-05       Impact factor: 2.533

View more
  42 in total

1.  Strategies for the preparation of bifunctional gadolinium(III) chelators.

Authors:  Luca Frullano; Peter Caravan
Journal:  Curr Org Synth       Date:  2011-08-01       Impact factor: 1.975

2.  Peptide- and saccharide-conjugated dendrimers for targeted drug delivery: a concise review.

Authors:  Jie Liu; Warren D Gray; Michael E Davis; Ying Luo
Journal:  Interface Focus       Date:  2012-03-21       Impact factor: 3.906

Review 3.  Macromolecules, dendrimers, and nanomaterials in magnetic resonance imaging: the interplay between size, function, and pharmacokinetics.

Authors:  Aaron Joseph L Villaraza; Ambika Bumb; Martin W Brechbiel
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

4.  Biodistribution of HPMA copolymer-aminohexylgeldanamycin-RGDfK conjugates for prostate cancer drug delivery.

Authors:  Mark P Borgman; Omer Aras; Sandra Geyser-Stoops; Edward A Sausville; Hamidreza Ghandehari
Journal:  Mol Pharm       Date:  2009 Nov-Dec       Impact factor: 4.939

Review 5.  Applications of orthogonal "click" chemistries in the synthesis of functional soft materials.

Authors:  Rhiannon K Iha; Karen L Wooley; Andreas M Nyström; Daniel J Burke; Matthew J Kade; Craig J Hawker
Journal:  Chem Rev       Date:  2009-11       Impact factor: 60.622

Review 6.  Multimodality imaging probes: design and challenges.

Authors:  Angelique Louie
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

7.  Preparation and In Vitro Characterization of Dendrimer-based Contrast Agents for Magnetic Resonance Imaging.

Authors:  Serhat Gündüz; Tanja Savić; Đorđe Toljić; Goran Angelovski
Journal:  J Vis Exp       Date:  2016-12-04       Impact factor: 1.355

8.  An effective targeted nanoglobular manganese(II) chelate conjugate for magnetic resonance molecular imaging of tumor extracellular matrix.

Authors:  Mingqian Tan; Xueming Wu; Eun-Kee Jeong; Qianjin Chen; Dennis L Parker; Zheng-Rong Lu
Journal:  Mol Pharm       Date:  2010-08-02       Impact factor: 4.939

9.  PAMAM-RGD conjugates enhance siRNA delivery through a multicellular spheroid model of malignant glioma.

Authors:  Carolyn L Waite; Charles M Roth
Journal:  Bioconjug Chem       Date:  2009-09-23       Impact factor: 4.774

10.  Gadolinium-conjugated dendrimer nanoclusters as a tumor-targeted T1 magnetic resonance imaging contrast agent.

Authors:  Zhiliang Cheng; Daniel L J Thorek; Andrew Tsourkas
Journal:  Angew Chem Int Ed Engl       Date:  2010       Impact factor: 15.336

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.